35 trends tracked about this subject — the full history, oldest to newest below.
Patients are facing restricted access to GLP-1 drugs like Ozempic and Wegovy due to high costs and restrictive insurance policies.
Australian regulators and medical reports link GLP-1 weight-loss drugs like Ozempic to a rare and severe risk of permanent vision loss.
New research links GLP-1 weight-loss medications like Ozempic and Mounjaro to an increased risk of hair loss in patients.
GLP-1 weight-loss medications are seeing a surge in adoption among adolescents and children globally, shifting treatment patterns for youth obesity.
A Georgia woman has joined a growing lawsuit connecting popular GLP-1 weight loss drugs to a rare and blinding eye condition.
Emerging trends in GLP-1 medications highlight an expansion beyond weight loss, including therapeutic retreats and rising use among young adults.
Rapid adoption of GLP-1 weight-loss drugs is sparking new debates over adolescent use, compounded safety, and the social stigma of medication.
A 54-year-old woman's emergency room hospitalization after a GLP-1 overdose highlights rising public safety concerns.
Medical research is exploring the intersection of GLP-1 receptor agonists and oncology, triggering debate over their potential role in cancer treatment.
A new oral GLP-1 receptor agonist is emerging as a potent weight-loss alternative, outperforming oral Ozempic in recent clinical trials.
Medical professionals are warning GLP-1 medication users about 'Ozempic feet,' a surprising new side effect emerging alongside rapid weight loss.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Ozempic’s skin effects are sparking a wave of cosmetic concern across Gen X.
Social media discourse and emerging clinical research are converging on the long-term potential of GLP-1 agonists beyond weight management.
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
GLP-1 weight‑loss drugs spark a wave of research, clinical guidance and market buzz as they expand beyond obesity treatment.
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
New research highlights concerns over the potential misuse of GLP-1 receptor agonist medications among individuals diagnosed with eating disorders.
Reports link Ozempic and similar GLP‑1 drugs to altered smell and taste, sparking a new “Ozempic mouth” discussion
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent research reveals that individuals using GLP-1 weight-loss medications exhibit a decline in physical activity levels.
16 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Colorado clears a federal hurdle to import cheaper prescription drugs from Canada
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
New clinical research presented at ASCO26 suggests a potential link between GLP-1 receptor agonist medications and reduced cancer risk.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
New research indicates that patients taking GLP-1 weight loss drugs are reducing their physical activity levels.
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
US employers may halt GLP-1 drug coverage in 2027 amid rising costs and usage spikes